 Laurie Gaspar
Concepts (490)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 100 | 2022 | 1164 | 6.610 |
Why?
| | Lung Neoplasms | 91 | 2023 | 2329 | 5.430 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 54 | 2022 | 1046 | 4.300 |
Why?
| | Radiosurgery | 44 | 2022 | 318 | 4.150 |
Why?
| | Cranial Irradiation | 20 | 2022 | 68 | 2.820 |
Why?
| | Small Cell Lung Carcinoma | 11 | 2023 | 89 | 2.690 |
Why?
| | Combined Modality Therapy | 62 | 2022 | 1209 | 1.290 |
Why?
| | Radiation Pneumonitis | 5 | 2021 | 28 | 1.260 |
Why?
| | Radiotherapy, Intensity-Modulated | 9 | 2018 | 128 | 1.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 30 | 2023 | 1573 | 1.190 |
Why?
| | Practice Guidelines as Topic | 13 | 2021 | 1493 | 1.160 |
Why?
| | Carcinoma, Small Cell | 8 | 2007 | 168 | 1.150 |
Why?
| | Neoplasm Staging | 39 | 2020 | 1293 | 1.120 |
Why?
| | Radiotherapy Dosage | 39 | 2023 | 249 | 1.070 |
Why?
| | Chemoradiotherapy | 8 | 2020 | 209 | 1.040 |
Why?
| | Brachytherapy | 12 | 2017 | 103 | 0.970 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 11 | 2021 | 123 | 0.920 |
Why?
| | Neoplasm Recurrence, Local | 21 | 2017 | 963 | 0.910 |
Why?
| | Glioblastoma | 18 | 2016 | 322 | 0.890 |
Why?
| | Radiation Oncology | 12 | 2022 | 75 | 0.890 |
Why?
| | Liver Neoplasms | 8 | 2009 | 643 | 0.770 |
Why?
| | Glioma | 15 | 2015 | 354 | 0.760 |
Why?
| | Adenocarcinoma | 13 | 2022 | 889 | 0.750 |
Why?
| | Aged | 102 | 2020 | 22083 | 0.740 |
Why?
| | Esophageal Neoplasms | 9 | 2008 | 293 | 0.720 |
Why?
| | Survival Rate | 31 | 2018 | 1875 | 0.710 |
Why?
| | Prognosis | 45 | 2022 | 3788 | 0.710 |
Why?
| | Humans | 221 | 2023 | 129116 | 0.710 |
Why?
| | Middle Aged | 118 | 2020 | 31074 | 0.680 |
Why?
| | Radiotherapy, Conformal | 8 | 2017 | 70 | 0.680 |
Why?
| | Clinical Trials as Topic | 18 | 2018 | 1000 | 0.670 |
Why?
| | Radiotherapy | 14 | 2017 | 185 | 0.660 |
Why?
| | Radiotherapy, Adjuvant | 16 | 2022 | 211 | 0.650 |
Why?
| | Neurosurgeons | 1 | 2019 | 18 | 0.630 |
Why?
| | Dacarbazine | 9 | 2016 | 97 | 0.630 |
Why?
| | Evidence-Based Medicine | 10 | 2021 | 718 | 0.610 |
Why?
| | Four-Dimensional Computed Tomography | 6 | 2021 | 28 | 0.600 |
Why?
| | Oncologists | 1 | 2018 | 37 | 0.560 |
Why?
| | Patient Selection | 10 | 2019 | 665 | 0.560 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 305 | 0.550 |
Why?
| | Aged, 80 and over | 45 | 2020 | 7064 | 0.550 |
Why?
| | Carcinoma, Squamous Cell | 10 | 2017 | 621 | 0.540 |
Why?
| | Male | 128 | 2022 | 63194 | 0.540 |
Why?
| | Cisplatin | 18 | 2021 | 298 | 0.530 |
Why?
| | Female | 131 | 2020 | 68510 | 0.520 |
Why?
| | Physician's Role | 1 | 2018 | 203 | 0.510 |
Why?
| | Antineoplastic Agents, Alkylating | 8 | 2016 | 69 | 0.510 |
Why?
| | Antineoplastic Agents | 20 | 2017 | 2060 | 0.500 |
Why?
| | Induction Chemotherapy | 2 | 2013 | 70 | 0.470 |
Why?
| | Adult | 90 | 2020 | 35510 | 0.460 |
Why?
| | Receptor Protein-Tyrosine Kinases | 5 | 2017 | 221 | 0.440 |
Why?
| | Survival Analysis | 24 | 2020 | 1265 | 0.440 |
Why?
| | Treatment Outcome | 36 | 2021 | 10226 | 0.430 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 531 | 0.420 |
Why?
| | Etoposide | 12 | 2021 | 150 | 0.400 |
Why?
| | Pro-Opiomelanocortin | 7 | 1989 | 17 | 0.380 |
Why?
| | Pneumonectomy | 2 | 2015 | 150 | 0.370 |
Why?
| | Retrospective Studies | 40 | 2022 | 14571 | 0.370 |
Why?
| | Astrocytoma | 9 | 2014 | 121 | 0.360 |
Why?
| | Societies, Medical | 7 | 2021 | 749 | 0.330 |
Why?
| | Protein Kinase Inhibitors | 4 | 2021 | 872 | 0.330 |
Why?
| | Pulmonary Ventilation | 4 | 2021 | 76 | 0.330 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 75 | 0.330 |
Why?
| | Melanoma | 5 | 2018 | 752 | 0.320 |
Why?
| | Guidelines as Topic | 2 | 2020 | 261 | 0.320 |
Why?
| | Chemotherapy, Adjuvant | 12 | 2017 | 376 | 0.320 |
Why?
| | Medical Oncology | 7 | 2021 | 274 | 0.320 |
Why?
| | Guideline Adherence | 4 | 2018 | 525 | 0.320 |
Why?
| | Karnofsky Performance Status | 11 | 2020 | 38 | 0.320 |
Why?
| | ErbB Receptors | 8 | 2022 | 603 | 0.310 |
Why?
| | Lung | 9 | 2021 | 3752 | 0.310 |
Why?
| | Quinazolines | 6 | 2014 | 243 | 0.300 |
Why?
| | Dose-Response Relationship, Radiation | 11 | 2019 | 133 | 0.300 |
Why?
| | Breast Neoplasms | 9 | 2020 | 2150 | 0.300 |
Why?
| | Iodine Radioisotopes | 6 | 2006 | 142 | 0.300 |
Why?
| | Re-Irradiation | 2 | 2018 | 8 | 0.290 |
Why?
| | Radiopharmaceuticals | 5 | 2014 | 166 | 0.290 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2007 | 27 | 0.290 |
Why?
| | Neoplasm Metastasis | 8 | 2019 | 616 | 0.290 |
Why?
| | Disease Progression | 13 | 2018 | 2613 | 0.290 |
Why?
| | Follow-Up Studies | 22 | 2018 | 4915 | 0.280 |
Why?
| | Anticonvulsants | 2 | 2019 | 198 | 0.270 |
Why?
| | Tumor Burden | 9 | 2017 | 283 | 0.270 |
Why?
| | Biomarkers, Tumor | 6 | 2021 | 1185 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 10 | 2018 | 2541 | 0.250 |
Why?
| | Paclitaxel | 5 | 2011 | 215 | 0.250 |
Why?
| | Prospective Studies | 22 | 2018 | 7079 | 0.250 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 215 | 0.240 |
Why?
| | Spinal Cord | 4 | 2018 | 354 | 0.240 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2005 | 271 | 0.230 |
Why?
| | Steroids | 2 | 2019 | 148 | 0.230 |
Why?
| | Taxoids | 5 | 2015 | 95 | 0.220 |
Why?
| | Central Nervous System | 2 | 2017 | 255 | 0.220 |
Why?
| | Carcinoma | 1 | 2006 | 214 | 0.220 |
Why?
| | Lymphatic Metastasis | 3 | 2017 | 318 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 9 | 2019 | 3383 | 0.220 |
Why?
| | Carcinoma, Renal Cell | 3 | 2018 | 180 | 0.220 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2019 | 72 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1363 | 0.200 |
Why?
| | Radiography | 8 | 2014 | 865 | 0.190 |
Why?
| | Necrosis | 3 | 2019 | 231 | 0.190 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2020 | 84 | 0.190 |
Why?
| | Medical Illustration | 2 | 2012 | 9 | 0.190 |
Why?
| | Organs at Risk | 2 | 2012 | 31 | 0.190 |
Why?
| | Ribs | 2 | 2012 | 33 | 0.190 |
Why?
| | Brachial Plexus | 2 | 2012 | 28 | 0.190 |
Why?
| | Neoplasms | 6 | 2020 | 2475 | 0.180 |
Why?
| | Professional Staff Committees | 4 | 2001 | 13 | 0.180 |
Why?
| | Oligodendroglioma | 4 | 2014 | 15 | 0.180 |
Why?
| | Esophagectomy | 1 | 2002 | 124 | 0.180 |
Why?
| | Testicular Neoplasms | 1 | 2022 | 102 | 0.170 |
Why?
| | Mutation | 4 | 2021 | 3700 | 0.170 |
Why?
| | Research Design | 7 | 2018 | 1040 | 0.170 |
Why?
| | Proportional Hazards Models | 8 | 2020 | 1210 | 0.170 |
Why?
| | Peptide Fragments | 4 | 1989 | 686 | 0.170 |
Why?
| | Thymus Neoplasms | 2 | 2017 | 22 | 0.160 |
Why?
| | Thymoma | 2 | 2017 | 31 | 0.160 |
Why?
| | Time Factors | 10 | 2019 | 6518 | 0.160 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 9 | 0.160 |
Why?
| | Esophagus | 2 | 2012 | 249 | 0.160 |
Why?
| | Metalloporphyrins | 3 | 2011 | 101 | 0.160 |
Why?
| | Maximum Tolerated Dose | 6 | 2010 | 194 | 0.160 |
Why?
| | Radiation Injuries | 5 | 2015 | 137 | 0.160 |
Why?
| | Congresses as Topic | 2 | 2019 | 215 | 0.160 |
Why?
| | Meningeal Neoplasms | 3 | 2017 | 93 | 0.160 |
Why?
| | Watchful Waiting | 1 | 2019 | 65 | 0.160 |
Why?
| | Expert Testimony | 1 | 2019 | 36 | 0.150 |
Why?
| | Aquaporin 4 | 1 | 2019 | 96 | 0.150 |
Why?
| | Gray Matter | 1 | 2019 | 82 | 0.150 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 89 | 0.150 |
Why?
| | Spinal Neoplasms | 1 | 2018 | 30 | 0.150 |
Why?
| | Cognition | 4 | 2013 | 1111 | 0.150 |
Why?
| | Intracranial Arteriovenous Malformations | 2 | 1995 | 51 | 0.140 |
Why?
| | Carboplatin | 4 | 2011 | 140 | 0.140 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 61 | 0.140 |
Why?
| | Kidney Neoplasms | 3 | 2018 | 350 | 0.140 |
Why?
| | Endpoint Determination | 1 | 2018 | 75 | 0.140 |
Why?
| | Receptor, ErbB-2 | 5 | 2020 | 336 | 0.140 |
Why?
| | Quality of Life | 5 | 2013 | 2693 | 0.140 |
Why?
| | Treatment Failure | 5 | 2014 | 343 | 0.140 |
Why?
| | Professional Competence | 1 | 2018 | 95 | 0.140 |
Why?
| | Genes, ras | 1 | 2017 | 98 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 174 | 0.140 |
Why?
| | Triazines | 2 | 2009 | 38 | 0.140 |
Why?
| | Decision Trees | 1 | 1997 | 89 | 0.140 |
Why?
| | Mortality | 1 | 2019 | 308 | 0.140 |
Why?
| | Pituitary Neoplasms | 5 | 1994 | 184 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 68 | 0.130 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 187 | 0.130 |
Why?
| | Brain | 5 | 2019 | 2628 | 0.130 |
Why?
| | Fluorouracil | 6 | 2004 | 197 | 0.130 |
Why?
| | Salvage Therapy | 4 | 2017 | 138 | 0.130 |
Why?
| | Hemangioma, Cavernous | 2 | 1993 | 13 | 0.130 |
Why?
| | Cohort Studies | 7 | 2019 | 5407 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 227 | 0.130 |
Why?
| | Antibodies | 1 | 2018 | 391 | 0.130 |
Why?
| | Pulmonary Atelectasis | 1 | 2015 | 13 | 0.130 |
Why?
| | Age Factors | 8 | 2017 | 3120 | 0.130 |
Why?
| | Accreditation | 2 | 2013 | 82 | 0.130 |
Why?
| | Patient Preference | 1 | 2018 | 186 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 519 | 0.120 |
Why?
| | Radiation-Sensitizing Agents | 5 | 2009 | 40 | 0.120 |
Why?
| | United States | 13 | 2022 | 13938 | 0.120 |
Why?
| | Postoperative Care | 1 | 2017 | 243 | 0.120 |
Why?
| | Medically Underserved Area | 1 | 2016 | 83 | 0.120 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 96 | 0.120 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2006 | 186 | 0.120 |
Why?
| | Central Nervous System Neoplasms | 1 | 2017 | 148 | 0.120 |
Why?
| | Risk Assessment | 3 | 2021 | 3260 | 0.110 |
Why?
| | Carmustine | 7 | 2010 | 50 | 0.110 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2017 | 191 | 0.110 |
Why?
| | Perfusion Imaging | 1 | 2014 | 56 | 0.110 |
Why?
| | Fibrosarcoma | 1 | 1993 | 21 | 0.110 |
Why?
| | Analysis of Variance | 5 | 2014 | 1271 | 0.110 |
Why?
| | Camptothecin | 2 | 2011 | 107 | 0.110 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 20 | 0.110 |
Why?
| | Cerebellar Neoplasms | 2 | 1996 | 156 | 0.110 |
Why?
| | Adolescent | 22 | 2017 | 20301 | 0.110 |
Why?
| | Receptors, Progesterone | 4 | 2020 | 345 | 0.110 |
Why?
| | Contraindications | 2 | 2008 | 88 | 0.110 |
Why?
| | Nelson Syndrome | 4 | 1987 | 4 | 0.110 |
Why?
| | Medulloblastoma | 2 | 1996 | 198 | 0.110 |
Why?
| | Pyrazoles | 2 | 2014 | 405 | 0.110 |
Why?
| | Disease-Free Survival | 6 | 2014 | 656 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 5 | 2019 | 864 | 0.100 |
Why?
| | Pyridines | 2 | 2014 | 477 | 0.100 |
Why?
| | Respiratory Function Tests | 1 | 2015 | 583 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1353 | 0.100 |
Why?
| | beta-Endorphin | 3 | 1989 | 8 | 0.100 |
Why?
| | Pancreatic Neoplasms | 1 | 2000 | 878 | 0.100 |
Why?
| | Radiotherapy, High-Energy | 4 | 2000 | 13 | 0.100 |
Why?
| | Particle Accelerators | 1 | 1991 | 10 | 0.090 |
Why?
| | Adrenocorticotropic Hormone | 3 | 1989 | 132 | 0.090 |
Why?
| | Bone Neoplasms | 3 | 2007 | 231 | 0.090 |
Why?
| | Radiation Protection | 2 | 2009 | 37 | 0.090 |
Why?
| | Quality Assurance, Health Care | 3 | 2009 | 317 | 0.090 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 511 | 0.090 |
Why?
| | Young Adult | 8 | 2017 | 12389 | 0.090 |
Why?
| | Hyperthermia, Induced | 1 | 1992 | 109 | 0.090 |
Why?
| | Technology, Radiologic | 1 | 2010 | 6 | 0.090 |
Why?
| | Radiotherapy, Computer-Assisted | 1 | 2010 | 12 | 0.090 |
Why?
| | Databases, Factual | 5 | 2017 | 1279 | 0.090 |
Why?
| | Bevacizumab | 3 | 2015 | 131 | 0.080 |
Why?
| | MEDLINE | 1 | 2009 | 20 | 0.080 |
Why?
| | Spine | 1 | 1991 | 159 | 0.080 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2002 | 71 | 0.080 |
Why?
| | Adenoma | 4 | 1994 | 215 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2739 | 0.080 |
Why?
| | Multivariate Analysis | 6 | 2020 | 1496 | 0.080 |
Why?
| | Neurosurgery | 1 | 2009 | 39 | 0.080 |
Why?
| | Risk Factors | 7 | 2021 | 9767 | 0.080 |
Why?
| | Adrenal Medulla | 1 | 1989 | 7 | 0.080 |
Why?
| | Neurotensin | 1 | 1989 | 12 | 0.080 |
Why?
| | Drug Therapy | 1 | 2009 | 76 | 0.080 |
Why?
| | Palliative Care | 5 | 2018 | 721 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 439 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2012 | 332 | 0.080 |
Why?
| | Fractures, Spontaneous | 1 | 1988 | 13 | 0.080 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 169 | 0.080 |
Why?
| | Piperidines | 1 | 2010 | 190 | 0.080 |
Why?
| | Ependymoma | 2 | 2009 | 176 | 0.080 |
Why?
| | Imaging, Three-Dimensional | 2 | 2010 | 535 | 0.080 |
Why?
| | Esophageal Fistula | 2 | 2000 | 18 | 0.080 |
Why?
| | Liver | 2 | 2008 | 1833 | 0.080 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 131 | 0.080 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 124 | 0.070 |
Why?
| | Pheochromocytoma | 1 | 1989 | 57 | 0.070 |
Why?
| | Respiratory Mechanics | 1 | 2008 | 64 | 0.070 |
Why?
| | Humeral Fractures | 1 | 1988 | 48 | 0.070 |
Why?
| | Positron-Emission Tomography | 2 | 2008 | 283 | 0.070 |
Why?
| | Femoral Fractures | 1 | 1988 | 74 | 0.070 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1989 | 83 | 0.070 |
Why?
| | Lymph Node Excision | 1 | 2009 | 165 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 5376 | 0.070 |
Why?
| | Craniopharyngioma | 1 | 2009 | 82 | 0.070 |
Why?
| | Chromatography, Gel | 4 | 1989 | 127 | 0.070 |
Why?
| | Kidney | 2 | 2005 | 1308 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 953 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2018 | 424 | 0.070 |
Why?
| | Radioimmunoassay | 4 | 1989 | 169 | 0.070 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1989 | 235 | 0.070 |
Why?
| | Seizures | 1 | 2009 | 399 | 0.060 |
Why?
| | Biomedical Research | 2 | 2009 | 647 | 0.060 |
Why?
| | Clinical Competence | 1 | 2013 | 1021 | 0.060 |
Why?
| | Whole Body Imaging | 1 | 2006 | 20 | 0.060 |
Why?
| | Vascular Diseases | 1 | 2009 | 236 | 0.060 |
Why?
| | Genetic Markers | 2 | 2017 | 339 | 0.060 |
Why?
| | Neoplasm Grading | 2 | 2020 | 284 | 0.060 |
Why?
| | Hepatitis B, Chronic | 1 | 2005 | 18 | 0.060 |
Why?
| | Linear Models | 3 | 2017 | 816 | 0.060 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 758 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 501 | 0.060 |
Why?
| | Strontium Radioisotopes | 2 | 2006 | 3 | 0.060 |
Why?
| | Databases as Topic | 1 | 2005 | 62 | 0.060 |
Why?
| | Diagnostic Imaging | 3 | 2009 | 330 | 0.060 |
Why?
| | Hemoglobins | 1 | 2007 | 337 | 0.060 |
Why?
| | Immunotherapy | 2 | 2022 | 588 | 0.060 |
Why?
| | Antiemetics | 1 | 2005 | 39 | 0.060 |
Why?
| | Gene Rearrangement | 2 | 2018 | 146 | 0.060 |
Why?
| | Anticoagulants | 1 | 2009 | 614 | 0.060 |
Why?
| | Peptides | 3 | 1985 | 911 | 0.060 |
Why?
| | Delivery of Health Care | 1 | 2012 | 894 | 0.060 |
Why?
| | Pituitary Hormones | 1 | 1984 | 16 | 0.060 |
Why?
| | Organ Size | 1 | 2005 | 441 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 861 | 0.060 |
Why?
| | Body Fluids | 1 | 1985 | 62 | 0.060 |
Why?
| | Retreatment | 3 | 2012 | 70 | 0.060 |
Why?
| | Cognition Disorders | 2 | 2010 | 497 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1269 | 0.060 |
Why?
| | Dexamethasone | 3 | 2012 | 340 | 0.060 |
Why?
| | Age Distribution | 1 | 2005 | 376 | 0.060 |
Why?
| | Feasibility Studies | 3 | 2011 | 862 | 0.060 |
Why?
| | Sex Distribution | 1 | 2005 | 359 | 0.060 |
Why?
| | Consensus | 2 | 2021 | 638 | 0.060 |
Why?
| | Regression Analysis | 2 | 2017 | 984 | 0.050 |
Why?
| | Erlotinib Hydrochloride | 2 | 2014 | 68 | 0.050 |
Why?
| | Hepatitis C, Chronic | 1 | 2005 | 154 | 0.050 |
Why?
| | Internship and Residency | 1 | 2013 | 1061 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2005 | 275 | 0.050 |
Why?
| | Preoperative Care | 1 | 2005 | 342 | 0.050 |
Why?
| | Propionates | 1 | 2003 | 33 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 256 | 0.050 |
Why?
| | Chromatography, Affinity | 3 | 1989 | 83 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2003 | 98 | 0.050 |
Why?
| | Societies | 1 | 2022 | 36 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2004 | 90 | 0.050 |
Why?
| | Pterygium | 1 | 2000 | 4 | 0.040 |
Why?
| | Algorithms | 2 | 2017 | 1621 | 0.040 |
Why?
| | Organizational Objectives | 4 | 2001 | 70 | 0.040 |
Why?
| | Esophagoscopy | 1 | 2002 | 195 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2015 | 3033 | 0.040 |
Why?
| | Ontario | 2 | 2017 | 89 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 189 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2000 | 115 | 0.040 |
Why?
| | Vincristine | 2 | 2010 | 110 | 0.040 |
Why?
| | BRCA1 Protein | 1 | 2020 | 65 | 0.040 |
Why?
| | Carcinoma, Bronchogenic | 1 | 1999 | 19 | 0.040 |
Why?
| | Spinal Cord Neoplasms | 1 | 1999 | 39 | 0.040 |
Why?
| | Neuropsychological Tests | 3 | 2013 | 1004 | 0.040 |
Why?
| | Carcinoma, Large Cell | 1 | 1999 | 15 | 0.040 |
Why?
| | Receptors, Estrogen | 2 | 2013 | 429 | 0.040 |
Why?
| | Medical Records | 2 | 2010 | 170 | 0.040 |
Why?
| | Reoperation | 2 | 2012 | 560 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2005 | 799 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2001 | 226 | 0.040 |
Why?
| | Estrogens | 1 | 2020 | 354 | 0.040 |
Why?
| | Thoracic Vertebrae | 1 | 2018 | 73 | 0.040 |
Why?
| | Child, Preschool | 7 | 2009 | 10450 | 0.040 |
Why?
| | Iridium Radioisotopes | 1 | 1997 | 3 | 0.030 |
Why?
| | Epidemiologic Methods | 1 | 2017 | 74 | 0.030 |
Why?
| | Colorado | 3 | 2014 | 4394 | 0.030 |
Why?
| | Aziridines | 2 | 1994 | 5 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 1997 | 50 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 189 | 0.030 |
Why?
| | Molecular Weight | 2 | 1989 | 331 | 0.030 |
Why?
| | Precision Medicine | 1 | 2020 | 384 | 0.030 |
Why?
| | Memory Disorders | 2 | 2010 | 158 | 0.030 |
Why?
| | Skin Neoplasms | 2 | 2017 | 833 | 0.030 |
Why?
| | Esophagitis | 2 | 2009 | 67 | 0.030 |
Why?
| | Benzoquinones | 2 | 1994 | 47 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 265 | 0.030 |
Why?
| | Respiration | 1 | 2017 | 191 | 0.030 |
Why?
| | Neutropenia | 2 | 2009 | 136 | 0.030 |
Why?
| | Supratentorial Neoplasms | 1 | 1996 | 19 | 0.030 |
Why?
| | Odds Ratio | 1 | 1999 | 1025 | 0.030 |
Why?
| | Heart | 1 | 2020 | 639 | 0.030 |
Why?
| | Meningioma | 1 | 1997 | 81 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2017 | 134 | 0.030 |
Why?
| | Sex Factors | 2 | 2014 | 1953 | 0.030 |
Why?
| | Pilot Projects | 3 | 2015 | 1567 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 109 | 0.030 |
Why?
| | Forecasting | 3 | 2001 | 358 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 45 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 973 | 0.030 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2014 | 7 | 0.030 |
Why?
| | Nuclear Medicine | 1 | 2014 | 7 | 0.030 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2014 | 10 | 0.030 |
Why?
| | Patient Safety | 1 | 2017 | 291 | 0.030 |
Why?
| | Vital Capacity | 1 | 2015 | 291 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 1997 | 254 | 0.030 |
Why?
| | Texas | 1 | 2014 | 227 | 0.030 |
Why?
| | Radioisotope Teletherapy | 1 | 1993 | 2 | 0.030 |
Why?
| | Cobalt Radioisotopes | 1 | 1993 | 7 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 387 | 0.030 |
Why?
| | Child | 9 | 2009 | 20805 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 206 | 0.030 |
Why?
| | Developing Countries | 1 | 2016 | 285 | 0.030 |
Why?
| | Spatial Analysis | 1 | 2013 | 21 | 0.030 |
Why?
| | Radiodermatitis | 1 | 1993 | 8 | 0.030 |
Why?
| | Vimentin | 1 | 1993 | 50 | 0.030 |
Why?
| | Radiometry | 1 | 2013 | 48 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2013 | 138 | 0.030 |
Why?
| | Observer Variation | 1 | 2014 | 315 | 0.030 |
Why?
| | Scalp | 1 | 1993 | 35 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2001 | 1013 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 1996 | 423 | 0.030 |
Why?
| | Time | 1 | 2013 | 75 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2016 | 430 | 0.030 |
Why?
| | Mitosis | 1 | 1993 | 178 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 1993 | 125 | 0.030 |
Why?
| | Medical Errors | 1 | 2013 | 104 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2013 | 153 | 0.020 |
Why?
| | Remission Induction | 2 | 2008 | 271 | 0.020 |
Why?
| | Radiology | 1 | 2014 | 162 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 593 | 0.020 |
Why?
| | International Agencies | 1 | 2011 | 29 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1417 | 0.020 |
Why?
| | Electrons | 1 | 1991 | 78 | 0.020 |
Why?
| | Breast Neoplasms, Male | 1 | 2011 | 29 | 0.020 |
Why?
| | Bronchography | 1 | 2010 | 10 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1825 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2715 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 2004 | 385 | 0.020 |
Why?
| | Fibrosis | 1 | 2013 | 522 | 0.020 |
Why?
| | Cell Nucleus | 1 | 1993 | 579 | 0.020 |
Why?
| | Procarbazine | 1 | 1990 | 8 | 0.020 |
Why?
| | Lomustine | 1 | 1990 | 14 | 0.020 |
Why?
| | Physics | 1 | 2010 | 17 | 0.020 |
Why?
| | Chromatin | 1 | 1993 | 478 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 119 | 0.020 |
Why?
| | Selection Bias | 1 | 2009 | 37 | 0.020 |
Why?
| | Clinical Trials Data Monitoring Committees | 1 | 2009 | 6 | 0.020 |
Why?
| | Hypophysectomy | 1 | 1989 | 15 | 0.020 |
Why?
| | Smoking | 1 | 2017 | 1466 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 156 | 0.020 |
Why?
| | Incidence | 1 | 2016 | 2635 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2564 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1671 | 0.020 |
Why?
| | Platinum | 1 | 2009 | 44 | 0.020 |
Why?
| | Adrenal Cortex | 1 | 1989 | 27 | 0.020 |
Why?
| | Certification | 1 | 2010 | 95 | 0.020 |
Why?
| | Bronchi | 1 | 2010 | 240 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 1988 | 13 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 14 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 138 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 40 | 0.020 |
Why?
| | beta-Lipotropin | 2 | 1985 | 2 | 0.020 |
Why?
| | Endorphins | 2 | 1985 | 8 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 471 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2065 | 0.020 |
Why?
| | Epinephrine | 1 | 1989 | 138 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 759 | 0.020 |
Why?
| | Motion | 1 | 2008 | 98 | 0.020 |
Why?
| | International Cooperation | 1 | 2008 | 173 | 0.020 |
Why?
| | Infant | 4 | 1999 | 8992 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 33 | 0.020 |
Why?
| | Fracture Fixation, Intramedullary | 1 | 1988 | 63 | 0.020 |
Why?
| | Reference Values | 1 | 1989 | 780 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2267 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 2008 | 136 | 0.020 |
Why?
| | Bleomycin | 1 | 2009 | 240 | 0.020 |
Why?
| | Creatinine | 1 | 1989 | 475 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1989 | 475 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1943 | 0.020 |
Why?
| | California | 1 | 2008 | 400 | 0.020 |
Why?
| | Southwestern United States | 1 | 2006 | 91 | 0.020 |
Why?
| | DNA Repair | 1 | 2008 | 205 | 0.020 |
Why?
| | Chromium Compounds | 1 | 2006 | 2 | 0.020 |
Why?
| | Sodium Iodide | 1 | 2006 | 3 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 291 | 0.020 |
Why?
| | Methadone | 1 | 1987 | 90 | 0.020 |
Why?
| | Polycythemia Vera | 1 | 2006 | 12 | 0.020 |
Why?
| | Pleural Effusion, Malignant | 1 | 2006 | 10 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 575 | 0.020 |
Why?
| | Hydrocephalus | 1 | 1987 | 108 | 0.020 |
Why?
| | Hyperthyroidism | 1 | 2006 | 28 | 0.020 |
Why?
| | Patient Isolation | 1 | 2006 | 16 | 0.020 |
Why?
| | Yttrium Radioisotopes | 1 | 2006 | 53 | 0.020 |
Why?
| | Ascites | 1 | 2006 | 44 | 0.020 |
Why?
| | DNA Damage | 1 | 2008 | 364 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2006 | 76 | 0.020 |
Why?
| | Organophosphorus Compounds | 1 | 2006 | 78 | 0.020 |
Why?
| | Chromatography | 1 | 1985 | 25 | 0.020 |
Why?
| | Concanavalin A | 1 | 1985 | 75 | 0.010 |
Why?
| | Phosphates | 1 | 2006 | 168 | 0.010 |
Why?
| | ACTH Syndrome, Ectopic | 1 | 1984 | 2 | 0.010 |
Why?
| | Organometallic Compounds | 1 | 2006 | 105 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2010 | 736 | 0.010 |
Why?
| | Occipital Lobe | 1 | 2004 | 24 | 0.010 |
Why?
| | Biotransformation | 1 | 1984 | 47 | 0.010 |
Why?
| | Carbohydrate Metabolism | 1 | 1984 | 60 | 0.010 |
Why?
| | Brain Edema | 1 | 2004 | 61 | 0.010 |
Why?
| | Genomics | 1 | 2009 | 716 | 0.010 |
Why?
| | Recurrence | 2 | 2000 | 1003 | 0.010 |
Why?
| | Arginine Vasopressin | 1 | 1984 | 41 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2006 | 182 | 0.010 |
Why?
| | Vomiting | 1 | 2004 | 128 | 0.010 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 1984 | 61 | 0.010 |
Why?
| | Oils | 1 | 1983 | 20 | 0.010 |
Why?
| | Bipolar Disorder | 1 | 1985 | 233 | 0.010 |
Why?
| | Motor Skills | 1 | 2004 | 91 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 2006 | 311 | 0.010 |
Why?
| | Immunologic Factors | 1 | 2003 | 229 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2001 | 90 | 0.010 |
Why?
| | Pain | 1 | 2006 | 760 | 0.010 |
Why?
| | Psychometrics | 1 | 2004 | 685 | 0.010 |
Why?
| | Opioid-Related Disorders | 1 | 1987 | 494 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 324 | 0.010 |
Why?
| | Thorax | 1 | 1999 | 41 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2438 | 0.010 |
Why?
| | Michigan | 1 | 1999 | 103 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1359 | 0.010 |
Why?
| | Cysts | 1 | 1999 | 108 | 0.010 |
Why?
| | Bias | 1 | 1999 | 195 | 0.010 |
Why?
| | Meninges | 1 | 1997 | 43 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1996 | 15 | 0.010 |
Why?
| | Mitomycin | 1 | 1996 | 31 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 5068 | 0.010 |
Why?
| | Biopsy | 1 | 1999 | 1086 | 0.010 |
Why?
| | Autoantibodies | 1 | 1983 | 1465 | 0.010 |
Why?
| | Decision Making | 1 | 2001 | 851 | 0.010 |
Why?
| | Cause of Death | 1 | 1996 | 393 | 0.010 |
Why?
| | Solutions | 1 | 1993 | 148 | 0.010 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1993 | 71 | 0.010 |
Why?
| | Cerebral Hemorrhage | 1 | 1993 | 107 | 0.010 |
Why?
| | Computer Simulation | 1 | 1995 | 941 | 0.010 |
Why?
| | Patient Compliance | 1 | 1994 | 562 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1989 | 172 | 0.000 |
Why?
| | Double-Blind Method | 1 | 1993 | 1865 | 0.000 |
Why?
| | Melanocyte-Stimulating Hormones | 1 | 1985 | 2 | 0.000 |
Why?
| | Lithium | 1 | 1985 | 37 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1996 | 2496 | 0.000 |
Why?
| | Brassica | 1 | 1983 | 4 | 0.000 |
Why?
| | Spain | 1 | 1983 | 36 | 0.000 |
Why?
| | Drug Synergism | 1 | 1984 | 358 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1983 | 84 | 0.000 |
Why?
| | Syndrome | 1 | 1983 | 337 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1984 | 1044 | 0.000 |
Why?
| | Sheep | 1 | 1984 | 829 | 0.000 |
Why?
| | Animals | 1 | 1984 | 34600 | 0.000 |
Why?
|
|
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|